Therapeutic Potentials of Curcumin in the Treatment of Non-Small-Cell Lung Carcinoma Publisher Pubmed



Salehi M¹ ; Movahedpour A^{2, 3} ; Tayarani A⁴ ; Shabaninejad Z^{5, 6} ; Pourhanifeh MH⁷ ; Mortezapour E⁸ ; Nickdasti A⁸ ; Mottaghi R⁹ ; Davoodabadi A¹⁰ ; Khan H¹¹ ; Savardashtaki A^{2, 6} ; Mirzaei H⁸
Source: Phytotherapy Research Published:2020

Abstract

Non-small-cell lung carcinoma (NSCLC) is one of the most lethal malignancies that include more than 80% of lung cancer cases worldwide. During the past decades, plants and plant-derived products have attracted great interest in the treatment of various human diseases. Curcumin, the turmeric isolated natural phenolic compound, has shown a promising chemo-preventive and anticancer agent. Numerous studies have shown that curcumin delays the initiation and progression of NSCLC by affecting a wide range of molecular targets and cell signalling pathways including NF-kB, Akt, MAPKS, BCL-2, ROS and microRNAs (miRNAs). However, the poor oral bioavailability and low chemical stability of curcumin remain as major challenges in the utilisation of this compound as a therapeutic agent. Different analogs of curcumin and new delivery systems (e.g., micelles, nanoparticles and liposomes) provided promising solutions to overcome these obstacles and improve curcumin pharmacokinetic profile. The present review focuses on current reported studies about anti-NSCLC effects of curcumin. NSCLC involved miRNAs whose expression is regulated by curcumin has also been discussed. Furthermore, recent researches on the use of curcumin analogs and delivery systems to enhance the curcumin benefits in NSCLC are also described. © 2020 John Wiley & Sons, Ltd.